SOLENO THERAPEUTICS INC (SLNO) Stock Price & Overview
NASDAQ:SLNO • US8342033094
Current stock price
The current stock price of SLNO is 32.79 USD. Today SLNO is down by -2.44%. In the past month the price decreased by -14.72%. In the past year, price decreased by -31.56%.
SLNO Key Statistics
- Market Cap
- 1.693B
- P/E
- 142.57
- Fwd P/E
- 7.63
- EPS (TTM)
- 0.23
- Dividend Yield
- N/A
SLNO Stock Performance
SLNO Stock Chart
SLNO Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to SLNO. When comparing the yearly performance of all stocks, SLNO is a bad performer in the overall market: 88.87% of all stocks are doing better.
SLNO Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to SLNO. SLNO has an excellent financial health rating, but there are some minor concerns on its profitability.
SLNO Earnings
On February 25, 2026 SLNO reported an EPS of 0.8 and a revenue of 91.73M. The company beat EPS expectations (10.35% surprise) and beat revenue expectations (1.56% surprise).
SLNO Forecast & Estimates
19 analysts have analysed SLNO and the average price target is 114.16 USD. This implies a price increase of 248.16% is expected in the next year compared to the current price of 32.79.
For the next year, analysts expect an EPS growth of 1768.07% and a revenue growth 154.6% for SLNO
SLNO Groups
Sector & Classification
SLNO Financial Highlights
Over the last trailing twelve months SLNO reported a non-GAAP Earnings per Share(EPS) of 0.23. The EPS increased by 105.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.75% | ||
| ROA | 3.63% | ||
| ROE | 4.55% | ||
| Debt/Equity | 0.11 |
SLNO Ownership
SLNO Latest News, Press Relases and Analysis
SLNO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.79 | 364.65B | ||
| AMGN | AMGEN INC | 15.14 | 188.631B | ||
| GILD | GILEAD SCIENCES INC | 15.54 | 175.177B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.5 | 116.358B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.65 | 77.963B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.18 | 41.258B | ||
| INSM | INSMED INC | N/A | 31.039B | ||
| NTRA | NATERA INC | N/A | 28.733B | ||
| BIIB | BIOGEN INC | 11.28 | 26.917B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.53 | 23.098B | ||
| MRNA | MODERNA INC | N/A | 20.683B | ||
| EXAS | EXACT SCIENCES CORP | 345.31 | 19.837B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.676B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SLNO
Company Profile
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is headquartered in Redwood City, California and currently employs 182 full-time employees. The company went IPO on 2014-10-23. The firm is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The firm has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
Company Info
IPO: 2014-10-23
SOLENO THERAPEUTICS INC
100 Marine Parkway, Suite 400
Redwood City CALIFORNIA 94065 US
CEO: Anish Bhatnagar
Employees: 182
Phone: 13026587581
SOLENO THERAPEUTICS INC / SLNO FAQ
What does SOLENO THERAPEUTICS INC do?
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is headquartered in Redwood City, California and currently employs 182 full-time employees. The company went IPO on 2014-10-23. The firm is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The firm has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
Can you provide the latest stock price for SOLENO THERAPEUTICS INC?
The current stock price of SLNO is 32.79 USD. The price decreased by -2.44% in the last trading session.
Does SOLENO THERAPEUTICS INC pay dividends?
SLNO does not pay a dividend.
What is the ChartMill rating of SOLENO THERAPEUTICS INC stock?
SLNO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is SOLENO THERAPEUTICS INC (SLNO) stock traded?
SLNO stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for SOLENO THERAPEUTICS INC?
SOLENO THERAPEUTICS INC (SLNO) operates in the Health Care sector and the Biotechnology industry.
Can you provide the number of employees for SOLENO THERAPEUTICS INC?
SOLENO THERAPEUTICS INC (SLNO) currently has 182 employees.